FDA label 86c24058-b1bc-4cd2-b382-bcb93d6b9f5e

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
32b1da94-1317-4b4f-ba02-f8c5d0efc167
SPL ID
86c24058-b1bc-4cd2-b382-bcb93d6b9f5e
Version
2
Effective date
2011-05-19
Source export date
2026-10-12
Source partition
1
Source file
https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-12/7928c8e8c6256620071a8b7e5b93eb8dfa543649c08d17a01ea02251012ba58c/drug-label-0001-of-0014.json.zip
Source manifest SHA-256
7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run
20261013T011858Z
Imported at
2026-10-13 01:26:10

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS Morphine can cause tolerance, psychological and physical dependence. Withdrawal will occur on abrupt discontinuation or administration of a narcotic antagonist. Interaction with Other Central-Nervous-System Depressants Morphine should be used with caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics, tricyclic antidepressants, and other CNS depressants (including alcohol). Respiratory depression, hypotension, and profound sedation or coma may result.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS THE MAJOR HAZARDS OF MORPHINE, AS OF OTHER NARCOTIC ANALGESICS, ARE RESPIRATORY DEPRESSION AND, TO A LESSER DEGREE, CIRCULATORY DEPRESSION, RESPIRATORY ARREST, SHOCK, AND CARDIAC ARREST HAVE OCCURED. The most frequently observed adverse reactions include lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. These effects seem to be more prominent in ambulatory patients and in those who are suffering severe pain. In such individuals, lower doses are advisable. Some adverse reactions may be alieviated in the ambulatory patient if he lies down. Other adverse reactions include the following: Central Nervous System - Euphoria, dysphona, weakness, headache, insomnia, agitation, disonentation, and visual disturbances. Gastrointestinal - Dry mouth, anorexia, constipation, and biliary tract spasm. Cardiovascular - Flushing of the face, bradycardia, palpitation, faintness and syncope. Allergic -Pruritus, urticana, other skin rashes, edema, and, rarely hemorrhagic urticana. Treatment of the most frequent adverse reactions Constipation Ample intake of water or other liquids should be encouraged. Concomitant administration of a stool softener and a peristatic stimulant with the narcotic analgesic can be an effetive preventive meassure for those patients in need of therapeutics. If elimination does not occur for two days, an enema should be administered to prevent impaction. In the event diarrhea occurs, seepage around fecal impaction is a possible cause to consider before antidiarrheal measures are employed. Nausea and Vomiting Phenothiazines and antihistamines can be effective treatments of nausea of the medullary and vestibular sources respectively. However, these drugs may potentiate the side effects of the narcotic or the anti-nauseant. Drowsiness (sedation) Once pain control is achieved, undesirable sedation can be minimized by titrating the dosage to a level that just maintains a tolerable pain or pain free state.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.